Does SNTA have any strong phase II data with a reasonable pt sample size?
should they really be studying patients with known cardio disease? I assume all obses patients have the risk factors. I thought they were avoiding people with cardio disease. Seems like asking for trouble.
sold a ton of higher price calls between Friday and this morning and bought back my higher strike short puts this morning. I am ready for the Immunoflopogen again. I don't trust any rally's in this stock. If it goes to $20+ I am ready to say thanks and move on.
ADP is just getting started, 3 is 1-2 years away. Several heavily shorted, high potential biotech's were up big today. I think it was get shorty day. I had to buy back some March 29 calls I sold against the stock and move out to the Jan 40. I think that if it reaches $40 I will just let it go, but who knows, I may end up buying those back also unless there's an acquisition.
Powerful bio-pharma rally underway. ACAD is flying!
maybe, ACAD is also flying. IMGN is only my 2nd best performer today. Maybe shorts are being called in on some stocks. If so, keep an eye on ARNA, it's one of the most heavily shorted/manipulated. This is some move!
sounds about right. Sold some calls here, probably helping to fuel the rally. Very unexpected on decent volume, must be an upgrade, or some news only known to institutions. DJ just sold some shares, so apparently he was not aware either. Nice to see a break out! Now I can spend more time on my day job and stop complaining until the offering or the good thing that is unknown is announced. WOW, major break out!
How is this early, the quarter ended about 7 weeks ago? We are more than half way through Q1 and will be almost 2/3 by then.
If they ever successfully design and complete a phase 2 trial on their own, with positive results, I will change my tune. Or, if they sign a blockbuster licensing deal for 289 or another compound that provides enough cash to avoid the next round of dilution, I will send DJ flowers.
It seems to be moving with the market x Beta to me. Nothing special happening at present. Keep an eye on the options. If it breaks past $25 on volume and we see some option volume, then it might be time to get excited. IMO, not advice.
I own other stocks, but none quite as disappointing and poorly managed considering the potential, technology, SGEN relative performance, etc. One day this will pay off (I think).
They hired another money-sucking executive that has nothing to do with advancing the pipeline, developing new drugs, etc. Maybe she will search for a new CEO, or fire some of the dead wood...not.
I really appreciate the manufactured dips. Now it's about time for you to exit! As my dad used to say, don't let the door hit you in the rear on the way out.
not sure anything short of an acquisition will get Immunoslug over $17-18. SGEN and now ECYT are kicking their asres.